Study guide

7.3 Severe Infections in the ICU

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

7.3 Severe Infections in the ICU

Key Takeaways Explain This Topic AI

Ventilator-associated pneumonia (VAP) empiric therapy must cover MRSA and dual-MDR Pseudomonas if the patient has risk factors or if local resistance rates are high (>10% for MRSA, >10% for Pseudomonas).

Central line-associated bloodstream infections (CLABSI) require prompt catheter removal for highly virulent organisms like S. aureus, Candida spp., or Pseudomonas aeruginosa.

Complicated intra-abdominal infections require aggressive source control (surgery/drainage); antimicrobial duration can be limited to 4 days if adequate source control is achieved.

Fulminant Clostridioides difficile infection in the ICU is characterized by hypotension, shock, ileus, or megacolon and is treated with high-dose oral vancomycin combined with IV metronidazole.

Pharmacists play a critical role in antimicrobial stewardship in the ICU, balancing adequate initial broad-spectrum coverage with rapid de-escalation.

Last updated: July 2026

Management of Severe ICU Infections

Patients in the Intensive Care Unit (ICU) are highly susceptible to healthcare-associated infections due to the presence of invasive devices (endotracheal tubes, central venous catheters, Foley catheters), altered immune function, and frequent exposure to broad-spectrum antibiotics. Effectively managing these infections is central to critical care pharmacy practice.

Ventilator-Associated Pneumonia (VAP)

VAP is defined as pneumonia developing >48 hours after endotracheal intubation. It is a major cause of morbidity and prolonged ICU length of stay.

Diagnosis

Diagnosis relies on clinical criteria (new or progressive radiographic infiltrate plus fever, leukocytosis/leukopenia, or purulent secretions) combined with microbiologic data. Non-invasive sampling (e.g., endotracheal aspiration) with semi-quantitative cultures is generally preferred over invasive sampling (e.g., bronchoalveolar lavage).

Empiric Antimicrobial Therapy

The 2016 IDSA/ATS guidelines emphasize tailoring empiric therapy based on local antibiograms and patient-specific risk factors for multi-drug resistant (MDR) pathogens.

MRSA Coverage: Include an agent active against MRSA (vancomycin or linezolid) if the patient has a risk factor for antimicrobial resistance (e.g., prior IV antibiotics within 90 days, ARDS preceding VAP, 5+ days of hospitalization), is in a unit where >10% of S. aureus isolates are MRSA, or if local prevalence is unknown.

Gram-Negative/Pseudomonal Coverage:

Single Coverage: One antipseudomonal agent (e.g., piperacillin-tazobactam, cefepime, meropenem) is sufficient if the patient has no risk factors for MDR pathogens and the ICU's resistance rate for the chosen agent is <10%.

Double Coverage: Two antipseudomonal agents from different classes (e.g., beta-lactam + aminoglycoside or fluoroquinolone) are required if the patient has risk factors for MDR pathogens or is in an ICU where >10% of Gram-negative isolates are resistant to the monotherapy agent.

Duration of Therapy

For both VAP and Hospital-Acquired Pneumonia (HAP), a 7-day course of antimicrobial therapy is recommended for most patients, rather than longer durations, provided they have a good clinical response.

Catheter-Related Bloodstream Infections (CRBSI)

CRBSIs, or Central Line-Associated Bloodstream Infections (CLABSIs), are significant complications of central venous catheters.

Management Strategy

Catheter Removal: The decision to remove the catheter depends on the pathogen and clinical status. The catheter must be removed if the patient is hemodynamically unstable, has severe sepsis/septic shock, or if the infection is caused by highly virulent organisms: Staphylococcus aureus , Pseudomonas aeruginosa , Candida species, or enterococci. In these cases, attempting to salvage the line is associated with high failure rates and metastatic infections (e.g., endocarditis).

Empiric Therapy: Initiate broad-spectrum therapy covering both Gram-positive (vancomycin) and Gram-negative pathogens (e.g., cefepime or piperacillin-tazobactam). The Gram-negative coverage is particularly important if the patient is critically ill, neutropenic, or has a femoral catheter.

Duration: If the catheter is removed, uncomplicated S. aureus bacteremia requires at least 14 days of therapy (some experts recommend up to 4-6 weeks to prevent endocarditis). Coagulase-negative staphylococci often require 5-7 days after removal. Uncomplicated Gram-negative bacteremia is typically treated for 7-14 days.

Complicated Intra-Abdominal Infections (cIAI)

Complicated intra-abdominal infections extend beyond the hollow viscus of origin into the peritoneal space (e.g., perforated appendicitis, diverticulitis with abscess, bowel perforation).

Source Control

Source control is the most critical intervention in cIAI. Without adequate surgical debridement or percutaneous drainage, antimicrobial therapy alone will fail.

Pharmacotherapy

Empiric regimens must cover enteric Gram-negative bacilli and anaerobes (e.g., Bacteroides fragilis ).

Community-Acquired (Mild/Moderate): Cefazolin or ceftriaxone + metronidazole, OR ertapenem.

Healthcare-Associated or High-Risk: Piperacillin-tazobactam, or cefepime + metronidazole, or a broad-spectrum carbapenem (meropenem, imipenem). Coverage for MRSA or Enterococcus may be added in high-risk patients with prior failures or specific colonizations.

Duration of Therapy

The STOP-IT trial revolutionized cIAI management. It demonstrated that in patients with adequate source control, a short course of antibiotics (4 days) is just as effective as a longer course (until resolution of systemic signs of infection). If source control is not achievable, longer durations are required.

Clostridioides difficile Infection (CDI) in the ICU

CDI is a major concern in the ICU due to the high volume of broad-spectrum antibiotic use. ICU patients frequently present with severe or fulminant CDI.

Definitions and Treatment

Severe CDI: Defined by a WBC count > 15,000 cells/mL or a serum creatinine > 1.5 mg/dL.

Treatment: Oral fidaxomicin 200 mg BID for 10 days or oral vancomycin 125 mg QID for 10 days.

Fulminant CDI: Characterized by hypotension, shock, ileus, or toxic megacolon.

Treatment: This requires aggressive therapy. The regimen of choice is high-dose oral vancomycin (500 mg QID) , either by mouth or via a nasogastric tube, combined with intravenous metronidazole (500 mg Q8H) . If an ileus is present, vancomycin enemas can also be added. Early surgical consultation for potential colectomy is vital.